Dipyridamole Inhibits Platelet Aggregation in Whole Blood

Summary

Dipyridamole possesses antithrombotic properties in the animal and in man but it does not inhibit platelet aggregation in plasma. We evaluated the effect of dipyridamole ex vivo and in vitro on platelet aggregation induced by collagen and adenosine- 5’-diphosphate (ADP) in human whole blood with an impedance aggregometer. Two hundred mg dipyridamole induced a significant inhibition of both ADP- and collagen-induced aggregation in human blood samples taken 2 hr after oral drug intake. Administration of the drug for four days, 400 mg/day, further increased the antiplatelet effect. A significant negative correlation was found between collagen-induced platelet aggregation in whole blood and dipyridamole levels in plasma (p <0.001). A statistically significant inhibition of both collagen (p <0.0025) and ADP-induced (p <0.005) platelet aggregation was also obtained by incubating whole blood in vitro for 2 min at 37° C with dipyridamole (3.9 μM). No such effects were seen in platelet-rich plasma, even after enrichment with leukocytes. Low-dose adenosine enhanced in vitro inhibition in whole blood.

Our results demonstrate that dipyridamole impedes platelet aggregation in whole blood by an interaction with red blood cells, probably involving adenosine.

Keywords

Adenosine - Dipyridamole - Impedance aggregometry - Platelet aggregation - Red blood cells - Whole blood

• References

• 1 Kadatz RA. Die pharmakologischen Eigenschaften der neuen koronarerweitemden Substanz 2,6-Bis(diaethanolamino)-4,8 dipiperidino-pyrimido(5,4-d)pyrimidin. Arzneimittelforsch 1959; 9: 39-45
• 2 Bunag RD, Douglas CR, Imai S, Berne RM. Influence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ Res 1964; 15: 83-88
• 3 Bom GV R, Cross MJ. Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J Physiol 1963; 166: 29P-30P
• 4 Emmons PR, Harrison MG J, Honour AJ, Mitchell JR. Effect of a pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature 1965; 208: 255-257
• 5 Didisheim P. Inhibition by dipyridamole of arterial thrombosis in rats. Thrombos Diathes Haemorrh 1968; 20: 256-266
• 6 Mayer JE, Hammond GL. Dipyridamole and aspirin tested against an experimental model of thrombosis. Ann Surg 1973; 178: 108-112
• 7 Pumphrey CW, Fuster V, Dewanjee MK. et al Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. Am J Cardiol 1983; 51: 591-595
• 8 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
• 9 Kincaid-Smith P. Modification of the vascular lesions of rejection in cadaveric renal allografts by dipyridamole and anticoagulants. Lancet 1969; 2: 920-922
• 10 Sullivan JM, Harken DW, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971; 284: 1391-1394
• 11 Packham MA, Mustard JF. Non steroidal anti-inflammatory drugs, pyrimido-pyrimidine compounds and tricyclic compounds. Effects on platelet functions In: Hirsh J, Cade JF, Gallus AS, Schonbaum E. (eds) Platelets. Drugs and Thrombosis Karger; Basel: 1975. pp 111-123
• 12 Weiss HJ. Antiplatelet therapy. N Engl J Med 1978; 298: 1344-1347
• 13 Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 1: 1286-1289
• 14 Steer ML, MacIntyre DE, Levine L, Salzman EW. Is prostacyclin a physiologically important circulating anti-platelet agent. Nature 1980; 283: 194-195
• 15 Di Minno G, Silver MJ, de Gaetano G. Ingestion of dipyridamole reduces inhibitory effect of prostacyclin on human platelets. Lancet 1979; 2: 701-702
• 16 Pickles H, Fish A, Hassan S, Burke C, Warrington S, O’Grady J. Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole. Clin Pharmacol Ther 1983; 33: 178-182
• 17 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005
• 18 Harker LA, Hanson SR. Experimental arterial thromboembolism in baboons: mechanism, quantitation and pharmacologic prevention. J Clin Invest 1979; 64: 559-569
• 19 Buchanan MR, Hirsh J. A comparison of the effects of aspirin and dipyridamole on platelet aggregation in vivo and ex vivo. Thromb Res 1978; 13: 517-529
• 20 Packham MA, Mustard JF. Pharmacology of platelet affecting drugs. Circulation 1980; 62 (suppl V) (Suppl. 05) V26-V41
• 21 Bom GV R, Görög P, Kratzer MA A. Aggregation of platelets in damaged vessels. Philos Trans R Soc London 1981; 294: 241-250
• 22 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-158
• 23 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
• 24 Challen A, Branch WJ, Cummings JH. Quantitation of platelet mass during aggregation in the electronic (Wellcome) whole blood aggregometer. J Pharmacol Methods 1982; 8: 115-122
• 25 Dresse A, Chevolet C, Delapierre D. et al Pharmacokinetics of oral dipyridamole (Persantine®) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229-234
• 26 Semeraro N, Locati D, Colucci M. Leukocyte-dependent platelet activation: an alternative pathway for initiation of blood clotting in inflammation. Agents Actions 1981; 11: 553-555
• 27 Li CC. Introduction to experimental statistics. McGraw-Hill; New-York: 1964
• 28 Philp RB, Lemieux JP V. Interactions of dipyridamole and adenosine on platelet aggregation. Nature 1969; 221: 1162-1164
• 29 Cucuianu MP, Nishizawa EE, Mustard JF. Effect of pyrimido- pyrimidine compounds on platelet function. J Lab Clin Med 1971; 77: 958-974
• 30 Scherathaner G, Miihlhauser I, Silberbauer K. Beta-thromboglobulin lowered by dipyridamole in diabetes. Lancet 1979; 2: 748-749
• 31 Mehta J, Mehta P, Pepine CJ, Conti CR. Platelet function studies in coronary artery disease. X. Effect of dipyridamole. Am J Cardiol 1981; 47: 1111-1114
• 32 Nenci GG, Berrettini M, Todisco T, Parise P. Enhanced plasma β-thromboglobulin in hypoxemia: effect of dipyridamole. N Engl J Med 1981; 304: 1044
• 33 Subbarao K, Rucinski B, Rausch MA, Schmid K, Niewiarowski S. Binding of dipyridamole to human platelets and to at acid glycoprotein and its significance for the inhibition of adenosine uptake. J Clin Invest 1977; 60: 936-943
• 34 Nunn B, White JP N. Inhibitors of platelet aggregation have different activity in blood than in platelet-rich plasma. Br J Pharmacol 1980; 70: 163P-164P
• 35 Mills DC B. The breakdown of adenosine diphosphate and of adenosine triphosphate in plasma. Biochem J 1966; 98: 32P-33P
• 36 Schrader J, Berne RM, Rubio R. Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 1972; 223: 159-166
• 37 Kolassa N, Pfleger K, Rummel W. Specificity of adenosine uptake into the heart and inhibition by dipyridamole. Eur J Pharmacol 1970; 9: 265-268
• 38 Summers A, Subbarao K, Rucinski B, Niewiarowski S. The effect of dipyridamole on adenosine uptake by platelets ex vivo. Thromb Res 1977; 11: 611-618
• 39 Crutchley DJ, Ryan US, Ryan JW. Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cul-tured cells derived from bovine pulmonary artery. J Clin Invest 1980; 66: 29-35
• 40 Roos H, Pfleger K. Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole. Mol Pharmacol 1972; 8: 417-425
• 41 Sollevi A, Ostergren J, Hiemdahl P, Fredholm BB, Fagrell B. The effect of dipyridamole on plasma adenosine levels and skin microcirculation in man. J Clin Chem Clin Biochem 1982; 20: 420
• 42 Haslam RJ, Lynham JA. Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sci 1972; 11: 1143-1154
• 43 Steer ML, Salzman EW. Cyclic nucleotides in hemostasis and thrombosis. In: Hamet P, Sands H. (eds) Advances in Cyclic Nucleotide Research. Raven Press; New-York: 1980. 12 71-92
• 44 Mills DC B, Smith JB. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’: 5’-cyclic monophosphate in platelets. Biochem J 1971; 121: 185-196
• 45 Best LC, McGuire MB, Jones PB B. et al Mode of action of dipyridamole on human platelets. Thromb Res 1979; 16: 367-379